Barclays’s ESSA Pharma EPIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-355
| Closed | -$68 | – | 5361 |
|
|
2025
Q3 | $68 | Hold |
355
| – | – | ﹤0.01% | 5293 |
|
|
2025
Q2 | $604 | Hold |
355
| – | – | ﹤0.01% | 5074 |
|
|
2025
Q1 | $561 | Hold |
355
| – | – | ﹤0.01% | 5076 |
|
|
2024
Q4 | $635 | Hold |
355
| – | – | ﹤0.01% | 5156 |
|
|
2024
Q3 | $2.15K | Buy |
+355
| New | +$1.95K | ﹤0.01% | 5078 |
|
|
2024
Q1 | – | Sell |
-971
| Closed | -$6.41K | – | 5165 |
|
|
2023
Q4 | $6.41K | Sell |
971
-317
| -25% | -$1.56K | ﹤0.01% | 5009 |
|
|
2023
Q3 | $3.98K | Buy |
+1,288
| New | +$3.71K | ﹤0.01% | 4409 |
|
|
2022
Q3 | – | Sell |
-1
| Closed | – | – | 4887 |
|
|
2022
Q2 | $0 | Sell |
1
-111
| -99% | -$620 | ﹤0.01% | 5089 |
|
|
2022
Q1 | $1K | Buy |
+112
| New | +$985 | ﹤0.01% | 4828 |
|
|
2021
Q4 | – | Sell |
-77,300
| Closed | -$618K | – | 4261 |
|
|
2021
Q3 | $618K | Buy |
+77,300
| New | +$1.23M | ﹤0.01% | 3068 |
|
Barclays's EPIX Position: Q4 2025 in Review
Barclays sold out of ESSA Pharma (EPIX) in Q4 2025, closing a stake of 355 shares — an estimated $68 sold.
Barclays first reported a position in EPIX in Q3 2021 and held it in 10 quarters. The position peaked at $618K in Q3 2021. 0 funds tracked by Wall St. Rank hold EPIX as of Q4 2025.
- Barclays reported no remaining ESSA Pharma position as of Q4 2025 after selling out during the quarter.
- Barclays sold 355 ESSA Pharma shares in Q4 2025, an estimated $68.
- Barclays first reported a position in ESSA Pharma in Q3 2021 and held it in 10 quarters.
- Barclays's ESSA Pharma position peaked at $618K in Q3 2021.
- 0 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.